세계의 혈장 시장 규모 : 성분별, 최종사용자별, 지역 범위별 및 예측

Global Blood Plasma Market Size By Component (Immunoglobulin, Albumin), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast

US $ 3,950 ￦ 5,411,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,644,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,344,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

혈장 시장 규모 및 예측

혈장 시장 규모는 2024년 412억 6,000만 달러로 평가되었고, 2026-2032년 연평균 9.2% 성장하여 2032년에는 834억 4,000만 달러에 달할 것으로 예측됩니다.

• 혈장은 혈액세포(적혈구, 백혈구, 혈소판)를 제거한 후 남는 황색을 띠는 액체 성분입니다. 전체 혈액량의 약 55%를 차지하는 혈장은 주로 물(약 90%)과 단백질, 전해질, 호르몬, 영양소, 노폐물로 구성되어 있습니다.
• 혈장은 이러한 물질을 전신으로 운반하는 중요한 매개체 역할을 하며, 혈압, pH 균형, 전반적인 항상성 유지에 필수적인 역할을 합니다.
• 혈장은 특히 수혈 의료 및 치료에서 수많은 의료적 용도를 가지고 있습니다. 혈장은 혈우병 환자를 위한 응고인자 농축제제 제조에 필수적이며, 다양한 면역 결핍을 치료하기 위한 면역글로불린 제제에도 사용됩니다.
• 또한, 알부민, 응고인자 등 혈장 유래 제품은 간질환, 쇼크, 화상 등의 상태를 관리하는 데 필수적입니다. 최근 혈장은 상처 치유 및 미용치료에 적용하는 등 재생의료의 가능성으로 주목받고 있습니다.

세계의 혈장 시장 역학

세계의 혈장 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 혈장 유래 치료제에 대한 수요 증가: 혈장 유래 치료제에 대한 수요 증가는 혈장 시장을 크게 견인하고 있습니다. 혈우병, 면역 결핍 등의 치료에는 효과적인 치료를 위해 혈장 유래 치료제가 필요하며, PPTA(Plasma Protein Therapeutics Association)에 따르면 혈장 유래 치료제 세계 시장은 2023년 286억 달러에 달할 것으로 예상되며, 2028년까지 6.8%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
• 헌혈에 대한 인식 증가: 헌혈의 중요성에 대한 인식이 높아짐에 따라 혈장의 가용성이 증가하고 있습니다. Plasma Protein Therapeutics Association(PPTA)에 따르면, 혈장 유래 치료제 세계 시장은 2023년 286억 달러에 달할 것으로 예상되며, 2028년까지 연평균 6.8%의 성장률을 보일 것으로 예측됩니다. CAGR은 6.8%로 예측되고 있습니다.
• 만성질환 발생률 증가: 자가면역질환과 같은 만성질환 증가로 인해 혈장 제품에 대한 수요가 증가하고 있습니다. 이러한 추세는 복잡한 건강 상태를 관리하는 데 있어 혈장의 중요한 역할을 강조하고 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 2023년 미국 인구의 약 6%가 자가면역질환을 앓고 있으며, 이는 2018년의 4.5%에서 증가한 수치입니다.
• 생명공학에 대한 투자 증가: 생명공학 및 연구에 대한 투자 증가로 혈장 유래 제품 개발이 강화되고 있습니다. 가공 및 제형의 혁신은 보다 효과적인 치료와 용도의 확대로 이어지고 있습니다. 미국 국립보건원(NIH)의 보고서에 따르면, 혈장 유래 치료 관련 연구비는 2023 회계연도에 12억 달러에 달할 것으로 예상되며, 이는 전년 대비 15% 증가한 수치입니다.
• 혈장 제품에 대한 규제적 지원 증가: 혈장 제품의 안전성과 유효성에 대한 규제 당국의 지원이 증가하면서 시장의 신뢰가 높아지고 있습니다. FDA는 2023년에 승인될 혈장 유래 치료제의 수가 2020년 대비 30% 증가할 것으로 예상하고 있으며, 이는 승인 절차가 보다 간소화되고, 이러한 제품에 대한 신뢰가 높아졌음을 반영하고 있습니다. 을 반영하고 있습니다.

주요 과제

• 규제 강화: 혈장 채취 및 사용에 대한 규제가 강화되면서 시장 확대에 걸림돌이 될 수 있습니다. 엄격한 가이드라인을 준수하는 것은 제조업체와 유통업체에게 복잡성과 비용을 증가시키고 있습니다.
• 기증자 안전에 대한 우려 증가: 기증자의 안전과 부작용 가능성에 대한 우려가 커지면서 혈장 공급에 영향을 미칠 수 있습니다. 이러한 우려는 헌혈 기피로 이어져 혈장 공급 부족으로 이어질 수 있습니다.
• 높아지는 사회적 인식 문제: 헌혈 및 혈장 제품과 관련된 사회적 인식 문제가 확대되어 시장 성장의 장벽이 될 수 있습니다. 잘못된 정보와 부정적인 감정은 잠재적 헌혈자 및 소비자의 발목을 잡을 수 있습니다.
• 대체요법과의 경쟁 심화: 대체요법 및 치료법과의 경쟁 심화는 혈장 시장에 도전이 될 수 있습니다. 새로운 기술이 대체 요법을 제공함으로써 기존 혈장 유래 요법에 대한 의존도를 낮출 수 있습니다.

주요 동향

• 면역글로불린 치료에 대한 관심 증가: 면역글로불린 치료에 대한 관심이 높아지면서 혈장 시장에 변화가 일어나고 있습니다. 면역결핍 및 자가면역질환에 대한 면역글로불린 치료의 효과에 대한 인식이 높아지면서 수요가 급증하고 있습니다. 의료 서비스 제공업체의 면역글로불린 요법 배합이 증가하고 혈장 수집 및 처리에 대한 투자가 확대되고 있습니다. 이러한 추세는 현대 의학에서 혈장 유래 제품의 중요한 역할을 강조하고 있습니다.
• 혈장 유래 생물학적 제제에 대한 수요 증가: 다양한 질환 관리에 필수적인 응고인자, 알부민 등 혈장 유래 생물학적 제제에 대한 수요가 증가하고 있습니다. 이러한 추세에 박차를 가하는 것은 만성질환, 수술, 외상치료에 대한 수요 증가입니다. 이러한 생명 유지 요법을 필요로 하는 환자가 늘어남에 따라 제조업체들은 이러한 수요를 충족시키기 위해 제품 라인을 확장하고 있습니다. 고품질 생물학적 제제의 중요성이 강조되면서 혈장 처리 기술의 혁신이 진행되고 있습니다.
• 자동 혈장채취의 채택 증가: 자동 혈장채취 기술의 채택이 증가하고 있으며, 산업에 혁명을 일으키고 있습니다. 자동화는 혈장 채취 과정의 효율성과 안전성을 향상시켜 수율을 높이고 기증자 경험을 개선합니다. 이러한 첨단 시스템을 도입하면 혈장 제품에 대한 수요 증가에 대응할 수 있습니다. 이러한 추세는 업무를 간소화할 뿐만 아니라 채혈 과정 중 불편함을 최소화하여 더 많은 기증자를 유치하는 데에도 도움이 됩니다.

목차

제1장 세계의 혈장 시장 서론

• 시장 개요
• 조사 범위
• 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 리스트

제4장 세계의 혈장 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 세계의 혈장 시장 : 성분별

• 개요
• 면역글로불린
• 알부민
• 응고인자 농축물
• 기타

제6장 세계의 혈장 시장 : 최종사용자별

• 개요
• 병원
• 클리닉
• 실험실

제7장 혈장 세계 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 기타
  • 라틴아메리카
  • 중동

제8장 세계의 혈장 시장 경쟁 구도

• 개요
• 기업의 시장 순위
• 주요 개발 전략

제9장 기업 개요

• CSL Behring
• Grifols
• Baxter International, Inc.
• Octapharma
• Shire(현Takeda Pharmaceutical Company 산하)
• Kedrion Biopharma
• China Biologic Products Holdings, Inc
• LFB Group, BIoTest AG.

제10장 부록

• 관련 조사

LSH

영문 목차

영문목차

Blood Plasma Market Size And Forecast

Blood Plasma Market size was valued at USD 41.26 Billion in 2024 and is projected to reach USD 83.44 Billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032.

• Blood plasma is the yellowish, liquid component of blood that remains after the blood cells (red cells, white cells, and platelets) have been removed. Comprising about 55% of total blood volume, plasma is primarily composed of water (around 90%), along with proteins, electrolytes, hormones, nutrients, and waste products.
• It serves as a crucial medium for transporting these substances throughout the body, playing an essential role in maintaining blood pressure, pH balance, and overall homeostasis.
• Plasma has numerous medical applications, particularly in transfusion medicine and therapeutic treatments. It is vital for the production of clotting factor concentrates for patients with hemophilia and is also used in the formulation of immunoglobulins to treat various immune deficiencies.
• Additionally, plasma-derived products, such as albumin and clotting factors, are critical in managing conditions like liver disease, shock, and burns. In recent years, plasma has also gained attention for its potential in regenerative medicine, including applications in wound healing and aesthetic treatments.

Global Blood Plasma Market Dynamics

The key market dynamics that are shaping the global blood plasma market include:

Key Market Drivers

• Rising Demand for Plasma-Derived Therapies: The rising demand for plasma-derived therapies is significantly driving the blood plasma market. Conditions such as hemophilia and immune deficiencies require these therapies for effective treatment. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Growing Awareness of Blood Donation: Growing awareness of the importance of blood donation is increasing the availability of plasma. Public health campaigns are encouraging more individuals to donate, thereby expanding the plasma supply. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases, such as autoimmune disorders, is boosting the need for plasma products. This trend emphasizes the essential role of plasma in managing complex health conditions. According to the Centers for Disease Control and Prevention (CDC), as of 2023, an estimated 6% of the U.S. population was living with an autoimmune disease, up from 4.5% in 2018.
• Rising Investment in Biotechnology: Rising investment in biotechnology and research is enhancing the development of plasma-derived products. Innovations in processing and formulation are leading to more effective therapies and expanded applications. The National Institutes of Health (NIH) reported that funding for research related to plasma-derived therapies reached USD 1.2 Billion in fiscal year 2023, a 15% increase from the previous year.
• Growing Regulatory Support for Plasma Products: Growing regulatory support for the safety and efficacy of plasma products is fostering market confidence. This supportive environment encourages manufacturers to invest in quality improvements and new product development. The FDA reported a 30% increase in the number of approved plasma-derived therapies in 2023 compared to 2020, reflecting a more streamlined approval process and growing confidence in these products.

Key Challenges:

• Increasing Regulatory Scrutiny: The increasing regulatory scrutiny surrounding blood plasma collection and use can hinder market expansion. Compliance with stringent guidelines adds complexity and costs for manufacturers and distributors.
• Rising Concerns over Donor Safety: Rising concerns about donor safety and the potential for adverse effects can affect plasma supply. These apprehensions may discourage individuals from donating, leading to shortages in plasma availability.
• Growing Public Perception Issues: Growing public perception issues related to blood donation and plasma products can create barriers to market growth. Misinformation or negative sentiments can deter potential donors and consumers alike.
• Growing Competition from Alternatives: Growing competition from alternative therapies and treatments poses a challenge to the blood plasma market. Emerging technologies may offer substitutes that reduce reliance on traditional plasma-derived therapies.

Key Trends

• Rising Focus on Immunoglobulin Therapies: The rising focus on immunoglobulin therapies is transforming the blood plasma market. As awareness grows about the effectiveness of these treatments for immune deficiencies and autoimmune diseases, demand is surging. Healthcare providers are increasingly prescribing immunoglobulin therapies, leading to greater investment in plasma collection and processing. This trend highlights the critical role of plasma-derived products in modern medicine.
• Growing Demand for Plasma-Derived Biologics: There is a growing demand for plasma-derived biologics, including clotting factors and albumin, essential for managing various medical conditions. This trend is fueled by an increasing prevalence of chronic diseases, surgical procedures, and trauma care needs. As more patients require these life-saving therapies, manufacturers are expanding their product lines to meet this demand. The emphasis on high-quality biologics is driving innovation in plasma processing technologies.
• Increasing Adoption of Automated Plasma Collection: The increasing adoption of automated plasma collection technologies is revolutionizing the industry. Automation improves the efficiency and safety of the collection process, resulting in higher yields and enhanced donor experience. As facilities implement these advanced systems, they can better meet the rising demand for plasma products. This trend not only streamlines operations but also helps attract more donors by minimizing discomfort during the collection process.

Global Blood Plasma Market Regional Analysis

Here is a more detailed regional analysis of the global blood plasma market:

North America

• North America leads the global blood plasma market, driven by advanced healthcare infrastructure, high awareness of plasma-derived therapies, and a well-established plasma collection network. The United States dominates the region's market share, with its robust regulatory framework and high plasma donation rates.
• According to the U.S. Food and Drug Administration, there were 943 licensed plasma collection centers in the country as of 2023, demonstrating the significant capacity for plasma collection and processing in the region.
• The region's dominance is further strengthened by the presence of major plasma fractionation companies and their ongoing investments in expanding production capabilities. Key players like CSL Limited and Grifols S.A. have been actively increasing their plasma collection and fractionation capacities to meet growing demand. In a recent development, Grifols announced in March 2024 the opening of a new plasma fractionation facility in North Carolina, USA, with an annual capacity of processing 6 million liters of plasma, potentially boosting the region's market position.

Asia Pacific

• The Asia Pacific region is experiencing rapid growth in the Blood Plasma Market, driven by improving healthcare infrastructure, increasing awareness of plasma-derived therapies, and rising prevalence of chronic diseases. Countries like China, India, and Japan are at the forefront of this expansion, with their governments investing heavily in healthcare systems and promoting plasma donation.
• According to China's National Medical Products Administration, the country's plasma-derived medicinal products market reached 30.8 billion yuan in 2023, highlighting the significant growth potential in the region.
• The market's growth is further propelled by the rising demand for immunoglobulins and other plasma-derived products for treating various immune deficiencies and rare diseases. Key players in the global blood plasma market are recognizing this potential and expanding their presence in Asia Pacific. In a recent development, Takeda Pharmaceutical Company Limited announced in February 2024 the completion of its new plasma fractionation facility in Guangzhou, China, with an annual production capacity of 1.2 million liters of plasma, aimed at meeting the growing demand for plasma-derived therapies in the region.

Global Blood Plasma Market: Segmentation Analysis

The Global Blood Plasma Market is segmented based on Component, End-User, And Geography.

Blood Plasma Market, By Component

• Immunoglobulin
• Albumin
• Coagulation Factor Concentrates
• Others

Based on Component, the Global Blood Plasma Market is bifurcated into Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Others. In the blood plasma market, immunoglobulin is the dominant component, primarily due to its critical role in treating various immune deficiencies and autoimmune disorders. Conversely, the albumin segment is rapidly growing, driven by its increasing applications in critical care settings, including surgeries and liver diseases, as well as its use in drug formulation. The rising demand for albumin-based therapies and its versatility in various medical applications are key factors contributing to this segment's expansion.

Blood Plasma Market, By End-User

• Hospitals
• Clinics
• Research Laboratories

Based on End-User, the Global Blood Plasma Market is bifurcated into Hospitals, Clinics, and Research Laboratories. In the blood plasma market, hospitals currently dominate as the primary end-user, driven by the high demand for plasma-derived therapies and transfusions in critical care settings. Meanwhile, the research laboratories segment is experiencing rapid growth, fueled by increasing investments in research related to plasma-derived products and their applications in various medical fields. The expansion of biopharmaceutical research and the development of new therapies utilizing plasma components are key factors contributing to the growth of this segment.

Blood Plasma Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Blood Plasma Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the blood plasma market, North America is the dominant region, primarily due to its advanced healthcare infrastructure, high prevalence of plasma-derived therapies, and significant investment in research and development. Conversely, the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditures, rising awareness of plasma therapies, and the expansion of healthcare facilities in countries like China and India. This growth is further supported by a rising incidence of chronic diseases and the demand for innovative treatment options, positioning Asia Pacific as a key area for future market expansion.

Key Players

The "Global Blood Plasma Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, Grifols, Baxter International, Inc., Octapharma, Shire (now part of Takeda Pharmaceutical Company), Kedrion Biopharma, Bio Products Laboratory, China Biologic Products Holdings, Inc., LFB Group, Biotest AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Plasma Market Key Developments

• In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments.
• In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD PLASMA MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD PLASMA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD PLASMA MARKET, BY Component

• 5.1 Overview
• 5.2 Immunoglobulin
• 5.3 Albumin
• 5.4 Coagulation Factor Concentrates
• 5.5 Others

6 GLOBAL BLOOD PLASMA MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Research Laboratories

7 GLOBAL BLOOD PLASMA MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL BLOOD PLASMA MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL Behring
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Grifols
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Baxter International, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Octapharma
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Shire (now part of Takeda Pharmaceutical Company)
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Kedrion Biopharma
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 China Biologic Products Holdings, Inc
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.9 LFB Group, Biotest AG.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 11.1 Related Research

관련자료